<!DOCTYPE html>
<html>
<head>
  <meta charset="utf-8">
  <title>Eli Lilly (LLY) Announces Promising Results For Jaypirca In CLL Phase 3 Trial</title>
</head>
<body>
  <a href="../../index.html">← Back to home</a>
  <h1>Eli Lilly (LLY) Announces Promising Results For Jaypirca In CLL Phase 3 Trial</h1>
  <ul>
<li>Pharmaceuticals industry, which had an 11.5% decline.</li>
<li>market, which gained 20.8% over the past year, and the U.S.</li>
<li>This announcement likely played a key role in the company’s 16% share price rise over the past month.</li>
<li>Over the past five years, Eli Lilly's total shareholder return, inclusive of share price appreciation and dividends, reached 416.18%, demonstrating significant longer-term performance.</li>
<li>Currently, the company's shares trade at US$727.21, showing a considerable discount to the consensus price target of US$891.62, indicating potential room for upward correction should these growth drivers effectively mate</li>
<li>We've spotted 2 weaknesses for Eli Lilly you should be aware of, and 1 of them is a bit unpleasant.</li>
<li>This article by Simply Wall St is general in nature.</li>
</ul>
<p><a href="https://finance.yahoo.com/news/eli-lilly-lly-announces-promising-172558054.html">Source</a> · 2025-09-08T17:25:58+00:00</p>
</body>
</html>